Drug Search Results
More Filters [+]

Oxybuprocaine

Alternative Names: oxybuprocaine
Latest Update: 2023-11-29
Latest Update Note: Clinical Trial Update

Product Description

Oxybuprocaine is a benzoate ester in which 4-amino-3-butoxybenzoic acidand 2-(diethylamino)ethanol have combined to form the ester bond; an ester-based local anaesthetic (ester "caine") used especially in ophthalmology and otolaryngology. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Oxybuprocaine)

Mechanisms of Action: Sodium Channel Binder

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Ocular,Topical

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Croatia | Czech | Denmark | Egypt | Estonia | Finland | France | Hungary | Iceland | Ireland | Israel | Jordan | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Sintetica
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Oxybuprocaine

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Anesthesia Related

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CHL.3-01-2021-M

P3

Not yet recruiting

Anesthesia Related

2024-09-30

62%

CHL.3-01-2021-M

P3

Not yet recruiting

Anesthesia Related

2024-09-30

62%

Recent News Events

Date

Type

Title